Y-mAbs Announces Appointment of Laura J. Hamill to its Board of Directors
April 24 2020 - 9:00AM
Y-mAbs Therapeutics, Inc., (the “Company” or “Y-mAbs”) (Nasdaq:
YMAB) a late-stage clinical biopharmaceutical company focused on
the development and commercialization of novel, antibody-based
therapeutic products for the treatment of cancer, today announced
the Board of Directors (the “Board”) nominates healthcare executive
Laura J. Hamill to be elected as a Class II director at the
Company’s 2020 annual meeting of stockholders (the “Annual
Meeting”).
”We are pleased to welcome Ms. Hamill as a board
member. Laura will add significant commercial experience to our
board, which will be of great value to our plans to augment our
commercial organization and bring our product candidates to
patients,” said Thomas Gad, Founder, Chairman, President, Head of
Business Development and Strategy of Y-mAbs.
Current member of the Board, Dr. Gregory Raskin,
will retire from the Board at the end of his current term. He will
continue to serve as a member of the Board until the Annual
Meeting. “On behalf of Y-mAbs’ board, shareholders and employees, I
would like to recognize and thank Dr. Raskin for his great
contributions to the successful development of Y-mAbs while serving
on the Board,” Thomas Gad continued.
Upon the expiration of Dr. Raskin’s current term
at the Annual Meeting, the size of the Board will be maintained at
eight directors. The other current Class II directors, James I.
Healy, M.D., and Ashutosh Tyagi, M.D., whose terms expire at the
Annual Meeting have informed the Board that they will stand for
re-election to the Board at the Annual Meeting.
About Laura J. Hamill
Ms. Hamill has extensive experience in the
biopharmaceutical industry, with over 30 years of global commercial
experience in a variety of executive leadership positions. Most
recently Ms. Hamill served as Executive Vice President, Worldwide
Commercial Operations, for Gilead Sciences, Inc., where she was
accountable for 2,200 employees and $22 billion in annual revenue.
There she led the global commercial strategic direction and
long-term planning. As a member of the executive team, she
contributed to the corporate strategy and overall governance of the
organization. Over an 18-year career at Amgen, Ms. Hamill
held a number of executive roles in the US and internationally. Her
last role as Senior Vice President and General Manager included
overall management of 2,000 employees, the strategic plans and
$20 billion of annual revenue for the U.S.
Commercial Operations. Ms. Hamill’s areas of therapeutic expertise
include inflammation, oncology, gene therapy, nephrology,
osteoporosis, cardiovascular disease, migraine, HIV, hepatology, GI
and anti-infectives. Since September 2019, Ms. Hamill has served on
the board of directors of AnaptysBio, Inc., a publicly traded
clinical-stage antibody-based biotechnology company. Ms. Hamill
holds a B.A. in business administration from the University of
Arizona.
About Y-mAbs
Y-mAbs is a late-stage clinical
biopharmaceutical company focused on the development and
commercialization of novel, antibody-based therapeutic products for
the treatment of cancer. The Company has a broad and advanced
product pipeline, including two pivotal-stage product
candidates—naxitamab and omburtamab—which target tumors that
express GD2 and B7-H3, respectively.
Forward-Looking Statements
Statements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of The Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about our business model and
development and commercialization plans; current and future
clinical and pre-clinical studies and our research and development
programs; regulatory, marketing and reimbursement approvals; rate
and degree of market acceptance and clinical utility as well as
pricing and reimbursement levels; retaining and hiring key
employees; our commercialization, marketing and manufacturing
capabilities and strategy; our intellectual property position and
strategy; additional product candidates and technologies;
collaborations or strategic partnerships and the potential benefits
thereof; expectations related to the use of our cash and cash
equivalents, and the need for, timing and amount of any future
financing transaction; our financial performance, including our
estimates regarding revenues, expenses, capital expenditure
requirements; developments relating to our competitors and our
industry; and other statements that are not historical facts. Words
such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’
‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’
‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’
‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’ and similar expressions
are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words. Our
product candidates and related technologies are novel approaches to
cancer treatment that present significant challenges. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various factors,
including but not limited to: risks associated with our financial
condition and need for additional capital; risks associated with
our development work; cost and success of our product development
activities and clinical trials; the risks of delay or failure to
receive approval of our drug candidates; the risks related to
commercializing any approved pharmaceutical product including the
rate and degree of market acceptance of our product candidates;
development of our sales and marketing capabilities and risks
associated with failure to obtain sufficient reimbursement for our
products; the risks related to our dependence on third parties
including for conduct of clinical testing and product manufacture;
our inability to enter into partnerships; the risks related to
government regulation; risks related to market approval, risks
associated with protection of our intellectual property rights;
risks related to employee matters and managing growth; risks
related to our common stock and other risks and uncertainties
affecting the Company including those described in the "Risk
Factors" section included in our Annual Report on Form 10-K and in
our other SEC filings. Any forward-looking statements contained in
this press release speak only as of the date hereof, and the
Company undertakes no obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Contact:
Y-mAbs Therapeutics, Inc. 230 Park Avenue, Suite 3350New York,
NY 10169USA
+1 646 885 8505
E-mail: info@ymabs.com
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Apr 2023 to Apr 2024